Search
Brepocitinib
go.drugbank.com/drugs/DB15003ApprovedInvestigationalBrepocitinib is an oral Janus kinase (JAK) and tyrosine kinase 2 (TYK2) inhibitor used to treat dermatomyositis in adults. It inhibits TYK2- and JAK1-mediated cytokine signaling, blocking phosphorylation of signal transducers and activat...
Categories: Cytochrome P-450 Substrates, P-glycoprotein inhibitorsGefapixant
go.drugbank.com/drugs/DB15097Approved[L48596] Gefapixant is a novel antagonist of the P2X3 receptor that works to reduce the cough reflex in patients with chronic cough.
Categories: P-glycoprotein substratesAvutometinib
go.drugbank.com/drugs/DB15254ApprovedInvestigationalAvutometinib is a small molecule kinase inhibitor targeted against RAF/MEK1, key regulators of the RAS/RAF/MEK/ERK (MAPK) pathway. The MAPK pathway is implicated in variety of cancers, playing a key role in tumor cell proliferation, diff...
Categories: Cytochrome P-450 Substrates, Cytochrome P-450 CYP3A SubstratesSotorasib
go.drugbank.com/drugs/DB15569ApprovedInvestigationalSotorasib, also known as AMG-510, is an acrylamide-derived KRAS inhibitor developed by Amgen. It is indicated in the treatment of adult patients with KRAS G12C mutant non-small cell lung cancer. This mutation makes up >50% of all KRAS...
Categories: P-glycoprotein inhibitors, Cytochrome P-450 SubstratesUlotaront
go.drugbank.com/drugs/DB15665InvestigationalUnlike other drugs used for this condition, SEP-363856 does not bind to the dopamine D2 receptors, but exerts actions on the trace amine–associated receptor 1 (TAAR1) and 5-hydroxytryptamine type 1A (5
Categories: Cytochrome P-450 CYP2B6 Inducers, Cytochrome P-450 SubstratesSelpercatinib
go.drugbank.com/drugs/DB15685ApprovedInvestigationalSelpercatinib is a kinase inhibitor with enhanced specificity for RET tyrosine kinase receptors (RTKs) over other RTK classes. Enhanced RET (Rearranged during transfection) oncogene expression is a hallmark of many cancers. Although mult...
Categories: P-glycoprotein inhibitors, P-glycoprotein substratesHomochlorcyclizine
go.drugbank.com/drugs/DB15979InvestigationalCategories: Cytochrome P-450 CYP2D6 Inhibitors, Cytochrome P-450 Enzyme InhibitorsGarlic oil
go.drugbank.com/drugs/DB15989InvestigationalCategories: Cytochrome P-450 CYP2C19 Inhibitors, Cytochrome P-450 CYP2C9 InhibitorsFinerenone
go.drugbank.com/drugs/DB16165ApprovedInvestigational[A236544] So far, finerenone is the only nonsteroidal mineralocorticoid receptor antagonist to be FDA approved. … [A236519,L34739] Patients with kidney disease, would originally be given [spironolactone] or [eplerenone] to antagonize the mineraclocorticoid receptor.
Categories: Cytochrome P-450 Substrates, Cytochrome P-450 CYP1A1 SubstratesPaltusotine
go.drugbank.com/drugs/DB16277ApprovedInvestigationalPaltusotine is a selective somatostatin receptor agonist: It mimics the biological actions of endogenous somatostatin, which activates the somatostatin 2 receptor (SST2) to block the secretion of growth
Categories: Somatostatin Receptor Agonists, P-glycoprotein inhibitors